Chronic Traumatic Encephalopathy Global Market Report 2025

The chronic traumatic encephalopathy market size has grown strongly in recent years. It will grow from $1.39 billion in 2024 to $1.51 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth during the historic period is due to greater awareness of sports-related head injuries, increased involvement in contact sports, a surge in military-related traumatic brain injuries, expanded research on neurodegenerative diseases, and improved access to diagnostic technologies.

The chronic traumatic encephalopathy market size is expected to see strong growth in the next few years. It will grow to $2.1 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. The growth projected for the forecast period is driven by increasing investments in neuroscience research, a rising demand for advanced diagnostic imaging, heightened emphasis on player safety regulations, expanding clinical studies on brain injuries, and growing public awareness about long-term brain health. Key trends during this period include progress in biomarker-based diagnostics, improved imaging techniques for early detection, development of disease-modifying treatments, innovations in wearable impact monitoring devices, and enhanced public awareness along with athlete screening initiatives.

The increasing number of head injuries is expected to drive growth in the chronic traumatic encephalopathy market in the future. Head injuries involve physical harm to the scalp, skull, or brain caused by an external impact or force. This rise in head injuries is largely due to more individuals participating in high-impact sports, which heightens the risk of traumatic brain injuries from collisions and accidents. Chronic traumatic encephalopathy (CTE) results from repeated head injuries that lead to the buildup of abnormal tau protein in the brain. This buildup progressively damages brain cells, causing cognitive decline and emotional issues. For example, in November 2024, the Tennessee Department of Health, a US government agency, reported that in 2023, 8,196 patients qualified for inclusion in the traumatic brain injury (TBI) Registry, representing a 2.4% increase from 2022. Thus, the growing occurrence of head injuries is fueling the expansion of the chronic traumatic encephalopathy market.

Leading companies in the chronic traumatic encephalopathy market are increasingly adopting advanced strategies, such as creating subsidiary companies, to speed up clinical trials and more effectively deliver innovative diagnostic and treatment options. A subsidiary is a separate legal entity owned or controlled by a parent company, which typically holds over 50% of its voting shares. This arrangement allows the parent company to enter new markets, reduce risks, and focus on specialized areas like research and development (R&D) or regional expansion. For example, in May 2023, Therapeutic Solutions International, a US biotechnology firm, established CTE Biologics Inc., a subsidiary to commercialize its clinical data and investigational new drug (IND) application for chronic traumatic encephalopathy (CTE) treatment using JadiCell universal adult stem cells. This subsidiary is dedicated to advancing JadiCell-based therapies for CTE - a neurodegenerative disorder commonly affecting athletes and military veterans - leveraging existing clinical data and ongoing regulatory engagement with the FDA to potentially begin formal clinical trials for this currently untreatable disease.

In March 2025, Enigma Biomedical USA Inc., a US biotechnology firm, collaborated with Boston University's chronic traumatic encephalopathy (CTE) center and the Concussion Legacy Foundation to promote early detection of CTE using advanced imaging techniques. This partnership focuses on validating 4R tau PET imaging biomarkers to enhance understanding and facilitate early diagnosis of CTE in living patients. The Concussion Legacy Foundation (CLF) is a US nonprofit organization, while the Boston University CTE Center is a US-based institution conducting cutting-edge research on chronic traumatic encephalopathy.

Major players in the chronic traumatic encephalopathy market are MedStar Health, NorthShore University Health System, Boston University, Mayo Foundation for Medical Education and Research, Craig Hospital, Quanterix Corporation, Life Molecular Imaging GmbH, Prothena Corporation plc, Annovis Bio Inc., Noveome Biotherapeutics Inc., Therapeutic Solutions International Inc., Kannalife Sciences Inc., Wund Healing Biopharmaceuticals, The Regents of The University of California, Novoron Bioscience Inc., FibroGenesis LLC, AgoneX Biopharmaceuticals Inc., Nexien Biopharma Inc., PresSura Neuro, and The Stern Lab.

North America was the largest region in the chronic traumatic encephalopathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in chronic traumatic encephalopathy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chronic traumatic encephalopathy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Chronic traumatic encephalopathy (CTE) is a neurological disorder caused by repeated head injuries over an extended period. It affects memory, cognitive abilities, and emotional regulation, resulting in confusion, mood fluctuations, and challenges in carrying out daily activities, often manifesting years after the initial injury.

The primary treatment methods for chronic traumatic encephalopathy include pharmacological therapies, rehabilitation programs, psychological support, surgical procedures, and alternative approaches. Pharmacological treatments involve using drugs such as anti-inflammatory agents and antidepressants to alleviate symptoms, decrease brain inflammation, and enhance daily functioning. Diagnosis is conducted through various methods including imaging scans, neurological assessments, biomarker analysis, among others. The condition is categorized into early-stage and advanced-stage CTE and is managed by different users such as hospitals, clinics, and research organizations.

The chronic traumatic encephalopathy market research report is one of a series of new reports that provides chronic traumatic encephalopathy market statistics, including the chronic traumatic encephalopathy industry global market size, regional shares, competitors with the chronic traumatic encephalopathy market share, detailed chronic traumatic encephalopathy market segments, market trends, opportunities, and any further data you may need to thrive in the chronic traumatic encephalopathy industry. This chronic traumatic encephalopathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chronic traumatic encephalopathy market consists of revenues earned by entities by providing services such as personalized medicine planning, telemedicine, genetic testing, occupational therapy, mental health support, cognitive therapy, and patient monitoring. The market value includes the value of related products and medical devices sold by the service providers or included within the service offering. The chronic traumatic encephalopathy market also includes sales of wearable health monitoring devices, brain imaging equipment, neuroprotective supplements, and biomarker assay kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.